First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France.
Azole resistance in Aspergillus fumigatus is an emerging public health concern. Recently, a novel fungicide-driven mutation in the cyp51A gene and its promoter, TR46/Y121F/T289A, leading to high-level resistance to voriconazole has been identified in The Netherlands, Belgium, Germany, Denmark, Tanzania, and India in both clinical and environmental samples. Here we report the first description of A. fumigatus carrying this mutation in France, in a cystic fibrosis patient, underlining the need for extensive monitoring of Aspergillus resistance.
Département de Parasitologie et Mycologie Médicale, Université de Nantes, Nantes Atlantique Universités, EA1155-IICiMed, Faculté de Pharmacie, Nantes, France Laboratoire de Parasitologie-Mycologie, Institut de Biologie, CHU de Nantes, Nantes, France.
Rose-Anne
RA
Lavergne
Département de Parasitologie et Mycologie Médicale, Université de Nantes, Nantes Atlantique Universités, EA1155-IICiMed, Faculté de Pharmacie, Nantes, France Laboratoire de Parasitologie-Mycologie, Institut de Biologie, CHU de Nantes, Nantes, France.
Florent
F
Morio
EA3800, Laboratoire de Parasitologie-Mycologie, Université de Rouen et CHU de Rouen, Rouen, France.
Loïc
L
Favennec
Department of Pneumology, Cystic Fibrosis Center, Rouen University Hospital, Rouen, France.
Stéphane
S
Dominique
Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Jacques F
http://orcid.org/0000-0003-3253-6080
JF
Meis
EA3800, Laboratoire de Parasitologie-Mycologie, Université de Rouen et CHU de Rouen, Rouen, France.
Gilles
G
Gargala
Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Paul E
PE
Verweij
Département de Parasitologie et Mycologie Médicale, Université de Nantes, Nantes Atlantique Universités, EA1155-IICiMed, Faculté de Pharmacie, Nantes, France Laboratoire de Parasitologie-Mycologie, Institut de Biologie, CHU de Nantes, Nantes, France patrice.le-pape@univ-nantes.fr.
Patrice
P
Le Pape
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000908:Antibodies, Fungal / Q000032:analysis; D001228:Aspergillosis / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000235:genetics*; D001393:Azoles / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000382:microbiology; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D025141:Drug Resistance, Fungal / Q000235:genetics*; D005060:Europe; D005602:France; D005656:Fungal Proteins / Q000235:genetics*; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D017964:Itraconazole / Q000494:pharmacology; D008297:Male; D009154:Mutation / Q000235:genetics; D012189:Retrospective Studies; D065819:Voriconazole / Q000494:pharmacology; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000908:Antibodies, Fungal; D001393:Azoles; D005656:Fungal Proteins; D017964:Itraconazole; D007073:Immunoglobulin E; D003577:Cytochrome P-450 Enzyme System; C465526:cytochrome P-450 CYP51A, Aspergillus; D065819:Voriconazole